Completion of ACTIV-2 Study

点击翻译按钮获取中文摘要

NIAID is sponsoring a clinical research study on novel therapeutics for COVID-19, which is one of the clinical studies for Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV). With an existing clinical trial infrastructure and multiple support contracts to provide services related to clinical trials support, regulatory support and pharmacy support, NIAID serves as the sponsor for the COVID-19 clinical trial entitled “A5401: Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)” also known as ACTIV-2. The objective of ACTIV-2 is to evaluate the safety and efficacy of multiple investigational agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly enhancing viral control in order to limit disease progression.